Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

3.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.9K
Preclinical Development: Overview01:28

Preclinical Development: Overview

5.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.2K
Clinical Trials01:16

Clinical Trials

9.8K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
9.8K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

867
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
867
Phase I Oxidative Reactions: Overview01:19

Phase I Oxidative Reactions: Overview

443
Phase I biotransformation, or functionalization, is a crucial chemical process that converts drugs and other xenobiotics into more water-soluble forms, facilitating expulsion from the body. It involves oxidative, reductive, and hydrolytic reactions that add or unveil polar functional groups on lipophilic substrates. Key players in phase I reactions are the mixed-function oxidases. Situated in liver cell microsomes, these enzymes predominantly carry out drug metabolism. They require molecular...
443
Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems01:19

Phase I Reactions: Oxidation of Aliphatic and Aromatic Carbon-Containing Systems

390
Phase I biotransformation reactions are integral to drug metabolism, predominantly involving oxidative, reductive, and hydrolytic transformations. Chief among these are oxidative reactions, which enhance the hydrophilicity of xenobiotics and introduce polar functional groups to facilitate their elimination from the body.
Oxidation reactions are fundamental in aromatic carbon-containing systems. An example is the hydroxylation of phenobarbital, a process that transforms it into...
390

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transplacental transfer of osimertinib and alectinib using an ex vivo human placental perfusion model.

Placenta·2026
Same author

Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1.

Nature·2026
Same author

[Pathophysiological rationale and management of anxio-depressive syndrome among cancer patients].

Bulletin du cancer·2025
Same author

Pharmacogenetics in oncology: Unveiling its potential in treatment personalization and beyond.

Bulletin du cancer·2025
Same author

Melanoma targeted therapies dabrafenib and trametinib cross the placental barrier in ex vivo human placental perfusions.

Journal of the American Academy of Dermatology·2025
Same author

[Intercontinental Multidisciplinary Oncology Videoconferencing between the South Pacific and the French mainland: Reasons for medical evacuation after more than 2000 cases of cancers discussed].

Bulletin du cancer·2025

Related Experiment Video

Updated: Oct 18, 2025

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

10.0K

Late phase 1 studies: concepts and outcomes.

Jose Carlos Benitez1, Arthur Geraud2, Matthieu Texier3

  • 1Department of Cancer Medicine, Gustave Roussy Cancer Center, Villejuif, France.

The Lancet. Oncology
|September 30, 2021
PubMed
Summary

Targeted cancer therapies often fail due to insufficient drug concentration, leading to relapse. A late phase 1 study is proposed to explore dose escalation in patients with acquired resistance, potentially restoring treatment efficacy.

More Related Videos

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.8K
A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.0K

Related Experiment Videos

Last Updated: Oct 18, 2025

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

10.0K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.8K
A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.0K

Area of Science:

  • Oncology
  • Clinical Pharmacology
  • Drug Development

Background:

  • Targeted therapies are crucial for cancers with oncogene addiction, but patient relapse within 12 months is common.
  • Drug resistance mechanisms and insufficient drug concentration contribute to treatment failure.
  • Current dosing strategies may not achieve optimal drug concentrations, impacting efficacy.

Purpose of the Study:

  • To introduce and define the concept of a late phase 1 study in clinical drug development.
  • To propose intrapatient dose escalation as a strategy to overcome treatment failure in specific patient populations.
  • To investigate alternative maximum tolerated doses (MTD) in patients with acquired resistance to targeted therapies.

Main Methods:

  • The proposed late phase 1 study involves dose escalation within individual patients.
  • Focuses on patients with initial benefit from targeted therapy who subsequently progressed without identified resistance alterations.
  • Aims to define an alternative MTD based on chronic exposure and subsequent progression.

Main Results:

  • Insufficient drug concentration is a frequent, yet underexplored, cause of targeted therapy failure.
  • The recommended phase 2 dose may not always represent the optimal therapeutic concentration.
  • Intrapatient dose escalation has the potential to increase drug concentration and restore efficacy.

Conclusions:

  • A late phase 1 study offers a novel approach to optimize targeted therapy dosing.
  • Addressing suboptimal drug concentrations through dose escalation may re-sensitize tumors to treatment.
  • This strategy could improve outcomes for patients experiencing treatment failure due to acquired resistance.